Stock Analysis on Net
Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity 
Quarterly Data

Edwards Lifesciences Corp., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Accounts payable 2.41 1.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accrued and other liabilities 9.44 9.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts payable and accrued liabilities (legacy) 0.00 0.00 11.24 10.71 11.98 12.09 13.22 11.88 13.52 12.60 12.08 11.41 16.47 11.10 10.27 11.57 13.22 12.64 10.95 12.23
Operating lease liabilities, current portion 0.30 0.30 0.33 0.37 0.38 0.36 0.37 0.41 0.39 0.40 0.43 0.41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Short-term debt 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.07 10.54 10.28 10.50 0.00 0.00 0.00
Contingent consideration liabilities 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.72 0.91 0.76 0.00 0.00
Current liabilities 12.14% 11.84% 11.57% 11.08% 12.35% 12.44% 13.59% 12.29% 13.91% 13.00% 12.51% 11.82% 16.47% 21.17% 20.81% 22.57% 24.63% 13.40% 10.95% 12.23%
Long-term debt 7.01 7.30 7.77 8.25 8.22 8.75 9.26 9.79 9.16 9.96 10.66 10.86 11.15 9.96 10.44 7.83 7.70 18.84 19.79 17.74
Contingent consideration liabilities 0.73 0.98 1.03 2.52 2.57 2.66 2.96 2.80 2.66 3.20 3.47 3.39 3.35 3.23 3.50 3.37 3.38 2.56 3.87 4.09
Taxes payable 2.23 2.33 2.48 2.98 2.97 3.15 3.33 3.94 3.65 3.96 4.25 4.74 4.87 4.44 4.63 4.99 6.92 0.00 0.00 0.00
Operating lease liabilities, long-term portion 0.81 0.79 0.83 0.93 1.00 1.04 1.03 0.92 0.91 0.88 0.90 0.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Uncertain tax positions 3.05 3.01 3.06 3.11 2.96 2.93 2.82 2.89 2.65 2.38 2.50 2.38 2.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Litigation settlement accrual 2.25 2.47 2.76 3.08 3.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other liabilities 3.14 3.38 3.50 3.48 3.49 7.12 7.25 3.16 3.13 2.68 2.91 2.87 2.82 4.79 4.97 5.52 5.47 7.58 8.19 8.56
Long-term liabilities 19.22% 20.25% 21.44% 24.35% 24.44% 25.65% 26.65% 23.50% 22.15% 23.06% 24.69% 25.15% 24.54% 22.42% 23.54% 21.71% 23.47% 28.98% 31.85% 30.39%
Total liabilities 31.36% 32.09% 33.00% 35.42% 36.79% 38.09% 40.24% 35.80% 36.06% 36.06% 37.20% 36.97% 41.01% 43.59% 44.35% 44.28% 48.10% 42.38% 42.79% 42.63%
Preferred stock, $.01 par value, no shares outstanding 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Common stock, $1.00 par value 7.55 7.86 8.35 8.84 8.79 9.34 9.86 3.60 3.36 3.65 3.89 3.95 4.04 3.61 3.76 3.66 3.72 3.86 4.76 5.09
Additional paid-in capital 20.00 20.14 20.60 20.75 19.87 20.32 20.61 27.58 25.02 26.32 27.13 26.50 26.00 22.51 21.27 21.10 20.49 20.58 24.66 25.26
Retained earnings 71.37 70.25 70.38 67.97 63.08 62.57 61.18 66.69 57.67 58.02 57.18 53.84 50.62 45.11 43.30 37.41 34.45 35.80 84.30 86.72
Accumulated other comprehensive loss -1.85 -1.90 -2.08 -2.39 -2.23 -2.32 -2.27 -2.50 -2.40 -2.61 -2.48 -2.58 -2.60 -2.33 -2.65 -2.08 -2.33 -2.60 -3.07 -3.80
Treasury stock, at cost -28.43 -28.44 -30.26 -30.59 -26.31 -28.00 -29.62 -31.16 -19.71 -21.43 -22.92 -18.67 -19.07 -12.48 -10.03 -4.36 -4.43 -0.01 -53.44 -55.90
Stockholders’ equity 68.64% 67.91% 67.00% 64.58% 63.21% 61.91% 59.76% 64.20% 63.94% 63.94% 62.80% 63.03% 58.99% 56.41% 55.65% 55.72% 51.90% 57.62% 57.21% 57.37%
Total liabilities and stockholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Edwards Lifesciences Corp. current liabilities as a percentage of total liabilities and stockholders’ equity increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Edwards Lifesciences Corp. long-term liabilities as a percentage of total liabilities and stockholders’ equity decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Edwards Lifesciences Corp. total liabilities as a percentage of total liabilities and stockholders’ equity decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Edwards Lifesciences Corp. stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.